Dr. Reddy’s DOJ and SEC FCPA probes end with no action
Rhea-AI Filing Summary
Dr. Reddy’s Laboratories Limited reports that the U.S. Department of Justice has closed its inquiry into alleged improper payments to healthcare professionals under the Foreign Corrupt Practices Act and has not recommended any enforcement action against the company. This follows an earlier letter from the U.S. Securities and Exchange Commission stating it had concluded a related investigation and did not intend to recommend enforcement. These outcomes relate to an anonymous complaint first disclosed in 2020 and formally notified to U.S. and Indian regulators, and they remove the risk of FCPA enforcement actions based on the investigated matters.
Positive
- Key U.S. investigations closed without enforcement: Both the U.S. Department of Justice and the Securities and Exchange Commission have ended their FCPA-related inquiries without recommending enforcement action, removing a significant prior regulatory and sanction risk tied to the anonymous 2020 complaint.
Negative
- None.
Insights
Key U.S. FCPA investigations into Dr. Reddy’s have been closed without enforcement.
Dr. Reddy’s Laboratories discloses that the U.S. Department of Justice’s Fraud Section has closed its Foreign Corrupt Practices Act inquiry and is not recommending enforcement. Earlier, the U.S. Securities and Exchange Commission likewise stated it did not intend to recommend enforcement action.
The investigations stemmed from an anonymous 2020 complaint about alleged improper payments to healthcare professionals, which the company reported to U.S. and Indian regulators and investigated with a U.S. law firm under board oversight. The disclosure notes that possible civil or criminal sanctions had previously been a risk.
The closure of both the DOJ inquiry and SEC investigation removes the specific enforcement overhang tied to these matters. Future regulatory or compliance developments, if any, would be expected to appear in subsequent company disclosures, but this update indicates no enforcement recommendations based on the information reviewed in these inquiries.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Dr. Reddy’s Laboratories (RDY) announce about the U.S. DOJ inquiry?
What was the outcome of the SEC investigation into Dr. Reddy’s (RDY)?
What triggered the investigations into Dr. Reddy’s Laboratories (RDY) in 2020?
Did Dr. Reddy’s (RDY) face any FCPA enforcement action from U.S. authorities?
How did Dr. Reddy’s (RDY) previously describe potential risks from these investigations?
AI-generated analysis. How Rhea-AI works. Not financial advice.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
March, 2026
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit Number |
| Description of Exhibits |
|
|
|
99.1 | Intimation dated March 06, 2026 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED (Registrant) | ||
|
|
|
|
Date: March 06, 2026 | By: | /s/ K Randhir Singh | |
|
| Name: | K Randhir Singh |
|
| Title: | Company Secretary |
| 3 |
Exhibit 99.1
| Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India
CIN: L85195TG1984PLC004507
Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com |
March 6, 2026
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/ Madam,
Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)
This is in furtherance to the Company’s intimation dated November 19, 2020, and the continuing disclosures made as notes to the quarterly financial results and the audited financial statements filed with exchanges thereafter, wherein it was informed that the Company commenced a detailed investigation into an anonymous complaint about allegation of improper payments to healthcare professionals in Ukraine and potentially in other countries, which could constitute violation of U.S. anti-corruption laws, including the U.S. Foreign Corrupt Practices Act. The matter was accordingly disclosed to the US Department of Justice (“DOJ”), United States Securities and Exchange Commission (“SEC”) and Securities Exchange Board of India (“SEBI”). It was also informed that, at the directions of the committee of the Company's Board of Directors, the Company had engaged a U.S. law firm to conduct the investigation. The Company had further disclosed that such investigations could result in government or regulatory enforcement actions against the Company in the United States and/or foreign jurisdictions and can also lead to civil and criminal sanctions under applicable laws.
Subsequently, through its intimation dated February 24, 2026, the Company informed that it had received a letter from the SEC dated February 23, 2026, stating that, based on the information available to it, the SEC had concluded the above-referenced investigation and did not intend to recommend any enforcement action against the Company at that time.
In this regard, the Company now wishes to inform that it has received a letter dated March 5, 2026, from the U.S. Department of Justice, Criminal Division, Fraud Section (the “Department”), stating that, based on the information available to it, the Department has closed its inquiry under the Foreign Corrupt Practices Act, 15 U.S.C. § 78dd-l, et seq. The Department has not recommended any enforcement action against the Company.
This is for your information and records.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR